Literature DB >> 16195778

Dramatic volume reduction of a large GH/TSH secreting pituitary tumor with short term Octreotide therapy.

John L D Atkinson1, Charles F Abboud, John I Lane.   

Abstract

A case is presented of a huge GH/TSH secreting tumor and marked volumetric reduction in size with only one week of Octreotide therapy. To our knowledge, this is the first reported case of such a dramatic volumetric response to short-term Octreotide therapy.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16195778     DOI： 10.1007/s11102-005-3279-2

Source DB:  PubMed          Journal:  Pituitary        ISSN： 1386-341X            Impact factor:   4.107


  13 in total

1.  Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).

Authors:  R Baldelli; A Colao; P Razzore; M L Jaffrain-Rea; P Marzullo; E Ciccarelli; E Ferretti; D Ferone; D Gaia; F Camanni; G Lombardi; G Tamburrano
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

2.  Effect of octreotide pretreatment on surgical outcome in acromegaly.

Authors:  A Colao; D Ferone; P Cappabianca; M L del Basso De Caro; P Marzullo; A Monticelli; A Alfieri; B Merola; A Calì; E de Divitiis; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1997-10       Impact factor: 5.958

3.  Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group.

Authors:  G Sassolas; A G Harris; A James-Deidier
Journal:  J Clin Endocrinol Metab       Date:  1990-08       Impact factor: 5.958

4.  Continuous infusion of octreotide in acromegaly.

Authors:  R A James; S Chatterjee; M C White; K Hall; N Moller; P Kendall-Taylor
Journal:  Lancet       Date:  1989-11-04       Impact factor: 79.321

5.  Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.

Authors:  A Colao; D Ferone; P Marzullo; P Cappabianca; S Cirillo; V Boerlin; I Lancranjan; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

Review 6.  Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.

Authors:  J C Gillis; S Noble; K L Goa
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

7.  Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.

Authors:  P Lundin; B Edén Engström; F A Karlsson; P Burman
Journal:  AJNR Am J Neuroradiol       Date:  1997-04       Impact factor: 3.825

8.  Sustained improvement in vision in a recurrent growth hormone secreting macroadenoma during treatment with octreotide in the absence of marked tumour shrinkage.

Authors:  John R Lindsay; Janet A Harding; Peter K Ellis; Brian Sheridan; A Brew Atkinson
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

9.  Octreotide as primary therapy for acromegaly.

Authors:  C B Newman; S Melmed; A George; D Torigian; M Duhaney; P Snyder; W Young; A Klibanski; M E Molitch; R Gagel; L Sheeler; D Cook; W Malarkey; I Jackson; M L Vance; A Barkan; L Frohman; D L Kleinberg
Journal:  J Clin Endocrinol Metab       Date:  1998-09       Impact factor: 5.958

10.  Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.

Authors:  J S Bevan; S L Atkin; A B Atkinson; P-M Bouloux; F Hanna; P E Harris; R A James; M McConnell; G A Roberts; M F Scanlon; P M Stewart; E Teasdale; H E Turner; J A H Wass; J M Wardlaw
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958
View more
  3 in total

1.  Dissociated responsiveness of a growth hormone- and thyrotropin-secreting pituitary adenoma to octreotide-long-acting release therapy: the intriguing case of Mister B.

Authors:  L Curtò; M Ragonese; M Losa; F Trimarchi; S Cannavò
Journal:  J Endocrinol Invest       Date:  2009-07-17       Impact factor: 4.256

2.  Pathologic and clinical features of pituitary adenomas showing TSH immunoreactivity.

Authors:  Nicholas A Tritos; Samatha Eppakayala; Brooke Swearingen; E Tessa Hedley-Whyte; Karen K Miller; Lisa B Nachtigall; Steven K Grinspoon; Beverly M K Biller; Anne Klibanski
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

Review 3.  A challenging TSH/GH co-secreting pituitary adenoma with concomitant thyroid cancer; a case report and literature review.

Authors:  Jee Hee Yoon; Wonsuk Choi; Ji Yong Park; A Ram Hong; Sung Sun Kim; Hee Kyung Kim; Ho-Cheol Kang
Journal:  BMC Endocr Disord       Date:  2021-08-30       Impact factor: 2.763
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.